THOR-707, a Novel Non Alpha IL-2, in Patients with Advanced/ Metastatic Solid Tumors
Time: 4:05 pm
day: Day Two
Details:
- Hypothesis: why non alpha
• Features: how THOR-707 spares the alpha receptor while binding to the
beta-gamma receptor
• Data: preliminary results from the ongoing Phase 1-2 clinical trial in
patients with solid tumors
